UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

29 Mar 2018

UCB Announces Filing Acceptance with the China Food and Drug Administration for CIMZIA® (certolizumab pegol) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

Read More
22 Mar 2018

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

Read More
22 Feb 2018

UCB Full Year Report 2017: UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

Read More
16 Feb 2018

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)

Read More
31 Jan 2018

UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders

Read More
29 Jan 2018

Transparency Notification 

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe

© 2007 - 2024 UCB S.A., Belgium. All rights reserved. Last updated on: January, 03, 2024